Evaluation of CONTOUR® USB BGMS on Glycaemic Control in Insulin-treated Diabetic Patients

Inclusion Criteria: * Type 2 diabetes * Therapy with insulin only (ICT) or ICT in combination with Metformin * HbA1c at baseline \> 7.5% and \< 11% * Patients at least 18 years of age * Patients willing to complete all study visits and study procedures including: * Testing their BG at least 3 times a day during the entire study. * Using the paper logbook provided (control group) * Using the Auto log meal-marker + reminder feature in CONTOUR Next USB regularly (TEST subjects only) * Using the Trends feature in CONTOUR Next USB regularly (TEST subjects only) * Uploading the CONTOUR Next USB meter to personal computer (subject must have personal computer at home or access to a computer - see system requirements in appendix for technical details). * Patients who are able to speak, read and understand German * Patients who are currently performing self-testing of blood glucose at home routinely (at least 3 times per day) for 4 weeks or more * Patients who are currently adjusting there insulin dosages themselves based on the self-testing of blood glucose at home * Written informed consent at beginning of the study Exclusion Criteria: * Patients who have been using CONTOUR Next USB meter regularly during the previous 12 months * Patients treated with oral antidiabetic drugs except for Metformin; or diet alone * Change of diabetes therapy within the last 3 months * Change of HbA1c level of more than ±0.5% within the last 3 months * Patients who are using a continuous blood glucose measurement system regularly * Patients with home health aides who assist with their BG testing and /or insulin adjustment * Patients with macroalbuminuria * Steroid therapy within the last 3 months. Topic or inhalative use is no exclusion criterion when not used regularly (more than 5 times a week). * Uncontrolled blood pressure ≥ 170/100 at screening * BMI \> 40 kg/m² * Anemia according to WHO-definition (hemoglobin \< 13 g/100 ml \[male\] or \< 12 g/100 ml \[female\]) * Creatinin \> 150 µmol/l and/or GFR \< 50 mmol/min/ 1.73m² (measured within the last 3 months before screening) * Operation with inpatient stay planned during the study * Current pregnancy or pregnancy planned during the study; or breastfeeding women. * Women with childbearing potential who are not practicing an acceptable method of birth control. Acceptable methods of birth control include tubal ligation, transdermal patch, intra uterine devices/systems (IUDs/IUSs), oral, implantable or injectable contraceptives, sexual abstinence, double barrier method and vasectomized partner * Alcohol or drug abuse within the last 3 months * Patients with the following impairments which, in the opinion of the investigator, would seriously compromise the integrity of the study: * Significant visual impairment * Significant hearing impairment * Cognitive disorder * Significant unstable co-morbidity (with notable change within the past 3 months) * Severe renal disease, disease with a strong impact on life expectancy * Inability to have or use and computer * Inability to use a meter correctly * Any other condition as per investigator's discretion * Current participation in another clinical study. Participation in another trial within 6 weeks before screening. * Employees of Bayer Vital Diabetes Care, the GWT or the University of Dresden